Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Celgene Corporation : Celgene 1st-Quarter Net Down 4.1% Amid Increased Costs

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/25/2013 | 02:25pm CET
   By Ben Fox Rubin 
 

Celgene Corp.'s (CELG) first-quarter profit fell 4.1% as the drug maker saw higher expenses offset stronger revenue from its Revlimid and Vidaza drugs.

The company raised its full-year guidance to a range of $5.55 to $5.65 a share in adjusted earnings from $5.50 to $5.60. It also backed its full-year product sales outlook.

Celgene has continued to post improved revenue, with its flagship blood-cancer treatment Revlimid grabbing more market share and sales of Vidaza, a blood-cancer treatment that lost patent exclusivity in May 2011, continuing to rise in the face of generic competition. The biopharmaceutical company also is expanding its core hematology franchise and building out new product lines in cancer and psoriasis as part of a strategy to achieve $12 billion in product sales by 2017.

Celgene reported a profit of $384.9 million, or 89 cents a share, down from $401.5 million, or 90 cents, a year earlier. Excluding items such as stock-based compensation, per-share earnings rose to $1.37 from $1.08.

Revenue grew 15% to $1.46 billion.

Analysts polled by Thomson Reuters had most recently forecast earnings of $1.35 a share on revenue of $1.47 billion.

Total costs and expenses rose 27%.

Revlimid sales were up 16% to $1 billion while Vidaza sales rose 10% to $204 million.

Shares closed Wednesday at $118.28 and were down 0.2% premarket. The stock has gained 51% so far this year.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

Order free Annual Report for Celgene Corp.

Visit http://djnweurope.ar.wilink.com/?ticker=US1510201049 or call +44 (0)208 391 6028

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELGENE CORPORATION
01/19 CELGENE : Anokion Announces Exclusive Strategic Collaboration With Celgene to De..
01/17 NASDAQ 100 MOVERS : Incy, dltr
01/12 TITAN PHARMACEUTICALS : Appoints Two New Board Members
01/10 AGIOS PHARMACEUTICALS : Announces Key Upcoming Milestones to Support Evolution t..
01/09 CELGENE CORPORATION (NASDAQ : CELG) Files An 8-K Results of Operations and Finan..
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
01/09 CELGENE CORP /DE/ : Results of Operations and Financial Condition, Financial Sta..
01/09 CELGENE CORPORATION : Announces Preliminary 2016 Unaudited Results and 2017 Fina..
01/08 INSIDER TRADING ACTIVITY ACCELERON P : XLRN) – COO Sold 2,500 shares of St..
01/08 INSIDER TRADING ACTIVITY ACCELERON P : XLRN) – EVP Sold 2,000 shares of St..
More news
Sector news : Bio Therapeutic Drugs
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/06DJSanofi Investors Count Cost of Praluent Ruling -- Update
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
06:30a The One Company I Was Most Impressed With Last Week
01/20 Implications Of The Latest Smash In Bristol-Myers Squibb Stock
01/20 Why Gilead Is Undervalued
01/20 The Most Important Keys To Celgene's Pipeline
01/19 ONE STEP CLOSER TO FINANCIAL FREEDOM : My 2016 Income Review
Advertisement
Financials ($)
Sales 2016 11 274 M
EBIT 2016 6 151 M
Net income 2016 2 435 M
Debt 2016 7 561 M
Yield 2016 -
P/E ratio 2016 37,62
P/E ratio 2017 20,50
EV / Sales 2016 8,42x
EV / Sales 2017 6,81x
Capitalization 87 334 M
More Financials
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Full-screen chart
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 140 $
Spread / Average Target 24%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mark J. Alles Chief Executive Officer & Director
Jacqualyn A. Fouse President, Chief Operating Officer & Director
Robert J. Hugin Executive Chairman
Peter N. Kellogg Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION-2.67%87 334
AMGEN, INC.5.79%115 062
GILEAD SCIENCES, INC.-0.84%93 553
REGENERON PHARMACEUTIC..-1.23%38 239
ACTELION LTD1.18%23 977
VERTEX PHARMACEUTICALS..10.45%20 182
More Results